Short Interest in Pulmatrix, Inc. (NASDAQ:PULM) Drops By 75.2%

Pulmatrix, Inc. (NASDAQ:PULM) saw a large decrease in short interest in August. As of August 14th, there was short interest totaling 4,171 shares, a decrease of 75.2% from the July 30th total of 16,792 shares. Based on an average trading volume of 8,523 shares, the short-interest ratio is currently 0.5 days. Currently, 0.1% of the company’s stock are sold short.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered shares of Pulmatrix from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, August 14th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Pulmatrix has an average rating of “Sell”.

Pulmatrix Price Performance

NASDAQ PULM traded down $0.01 during midday trading on Friday, hitting $1.51. 3,317 shares of the company traded hands, compared to its average volume of 11,996. The company has a market cap of $5.51 million, a PE ratio of -1.37 and a beta of 1.91. The company’s 50-day simple moving average is $1.64 and its 200-day simple moving average is $1.68. Pulmatrix has a 52 week low of $1.16 and a 52 week high of $5.50.

Pulmatrix (NASDAQ:PULM) last announced its quarterly earnings results on Thursday, August 13th. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.00) by $1.71.

Hedge Funds Weigh In On Pulmatrix

A number of large investors have recently added to or reduced their stakes in PULM. BlackRock Inc. purchased a new stake in shares of Pulmatrix during the second quarter valued at about $93,000. DRW Securities LLC bought a new position in shares of Pulmatrix during the 4th quarter worth approximately $46,000. Finally, Dimensional Fund Advisors LP purchased a new stake in Pulmatrix during the third quarter valued at approximately $52,000. 11.84% of the stock is currently owned by institutional investors.

About Pulmatrix

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).